Resetting the transcription factor network reverses terminal chronic hepatic failure

Journal of Clinical Investigation

Volumn 125, Issue 4, 2015, Pages 1533-1544

  Nishikawa, Taichiro ^a,b   Bell, Aaron ^c,d   Brooks, Jenna M ^a   Setoyama, Kentaro ^a   Melis, Marta ^a   Han, Bing ^a   Fukumitsu, Ken ^c,d   Handa, Kan ^c,d   Tian, Jianmin ^c   Kaestner, Klaus H ^e   Vodovotz, Yoram ^d   Locker, Joseph ^c   Soto Gutierrez, Alejandro ^c,d   Fox, Ira J ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; CARBON TETRACHLORIDE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYTOCHROME P450; CYTOCHROME P450 3A4; DNA BINDING PROTEIN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 3BETA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; ORNITHINE CARBAMOYLTRANSFERASE; PREALBUMIN; TRANSFERRIN; TYROSINE AMINOTRANSFERASE; FOXA2 PROTEIN, RAT; HEPATOCYTE NUCLEAR FACTOR 4; HNF1A PROTEIN, RAT; HNF4A PROTEIN, RAT; HYBRID PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRANSCRIPTION FACTOR; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DEDIFFERENTIATION; CELL LINEAGE; CHRONIC LIVER FAILURE; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE REGULATORY NETWORK; LIVER CELL; LIVER FUNCTION; MALE; NONHUMAN; NUCLEAR REPROGRAMMING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RAT; SOMATIC CELL; TERMINAL DISEASE; ANIMAL; BIOSYNTHESIS; CARBON TETRACHLORIDE POISONING; CELL CULTURE; COMPLICATION; DEPENDOPARVOVIRUS; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; LEWIS RAT; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER FAILURE; METABOLISM; PATHOLOGY; PHYSIOLOGY; THERAPEUTIC USE;

ANIMALS; CARBON TETRACHLORIDE POISONING; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL DEDIFFERENTIATION; CELLS, CULTURED; DEPENDOVIRUS; DISEASE PROGRESSION; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GENETIC THERAPY; GENETIC VECTORS; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HEPATOCYTE NUCLEAR FACTOR 3-BETA; HEPATOCYTE NUCLEAR FACTOR 4; HEPATOCYTES; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER FAILURE; MALE; PPAR ALPHA; RATS; RATS, INBRED LEW; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTOME; TRANSDUCTION, GENETIC;

EID: 84926301373     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI73137     Document Type: Article

References (45)

1. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005;42(suppl 1):S100-S107.
2. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004;350(16):1646-1654.
3. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-851.
4. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol. 2003;38(suppl 1):S38-S53.
5. Martinez-Hernandez A, Martinez J. The role of capillarization in hepatic failure: studies in carbon tetrachloride-induced cirrhosis. Hepatology. 1991;14(5):864-874.
6. Pessayre D, Lebrec D, Descatoire V, Peignoux M, Benhamou JP. Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology. 1978;74(3):566-571.
7. Vaubourdolle M, et al. Evidence of the intact hepatocyte theory in alcoholic cirrhosis. Scand J Gastroenterol. 1989;24(4):467-474.
8. Lopez PM, Martin P. Update on liver transplantation: indications, organ allocation, and long-term care. Mt Sinai J Med. 2006;73(8):1056-1066.
9. Choi J, Ou JH. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):G847-G851.
10. Kitada T, Seki S, Iwai S, Yamada T, Sakaguchi H, Wakasa K. In situ detection of oxidative DNA damage, 8-hydroxydeoxyguanosine, in chronic human liver disease. J Hepatol. 2001;35(5):613-618.
11. Grattagliano I, et al. Mitochondria in chronic liver disease. Curr Drug Targets. 2011;12(6):879-893.
12. Krahenbuhl S. Alterations in mitochondrial function and morphology in chronic liver disease: pathogenesis and potential for therapeutic intervention. Pharmacol Ther. 1993;60(1):1-38.
13. Liu L, et al. The microenvironment in hepatocyte regeneration and function in rats with advanced cirrhosis. Hepatology. 2012;55(5):1529-1539.
14. Hoare M, Das T, Alexander G. Ageing, telomeres, senescence, and liver injury. J Hepatol. 2010;53(5):950-961.
15. Lechel A, Manns MP, Rudolph KL. Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma. J Hepatol. 2004;41(3):491-497.
16. Kobayashi N, et al. Hepatocyte transplantation in rats with decompensated cirrhosis. Hepatology. 2000;31(4):851-857.
17. Marro S, et al. Direct lineage conversion of terminally differentiated hepatocytes to functional neurons. Cell Stem Cell. 2011;9(4):374-382.
18. Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-872.
19. Berasain C, et al. Expression of Wilms' tumor suppressor in the liver with cirrhosis: relation to hepatocyte nuclear factor 4 and hepatocellular function. Hepatology. 2003;38(1):148-157.
20. Limaye PB, et al. Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development. Lab Invest. 2008;88(8):865-872.
21. Locker J. Transcriptional control of hepatocyte differentiation. In: Monga SP, ed. Molecular Pathology of Liver Diseases. New York, New York, USA: Springer; 2011:193-201.
22. Sladek FM, Seidel S. Heaptocyte nuclear factor 4a. In: McCabe TPBE, ed. Nuclear Receptors and Genetic Disease. London, United Kingdom: Academic Press; 2001.
23. Bolotin E, et al. Integrated approach for the identification of human hepatocyte nuclear factor 4a target genes using protein binding microarrays. Hepatology. 2010;51(2):642-653.
24. Nagata H, Ito M, Cai J, Edge AS, Platt JL, Fox IJ. Treatment of cirrhosis and liver failure in rats by hepatocyte xenotransplantation. Gastroenterology. 2003;124(2):422-431.
25. Kyrmizi I, Hatzis P, Katrakili N, Tronche F, Gonzalez FJ, Talianidis I. Plasticity and expanding complexity of the hepatic transcription factor network during liver development. Genes Dev. 2006;20(16):2293-2305.
26. Odom DT, et al. Core transcriptional regulatory circuitry in human hepatocytes. Mol Syst Biol. 2006;2:2006.0017.
27. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol. 2001;21(4):1393-1403.
28. Parviz F, et al. Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet. 2003;34(3):292-296.
29. Sladek FM, Zhong WM, Lai E, Darnell JE, Darnell JE Jr. Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev. 1990;4(12):2353-2365.
30. Gonzalez FJ. Regulation of hepatocyte nuclear factor 4 alpha-mediated transcription. Drug Metab Pharmacokinet. 2008;23(1):2-7.
31. Michalopoulos GK. Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol. 2010;176(1):2-13.
32. Ponnazhagan S, et al. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene. 1997;190(1):203-210.
33. Grimm D, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol. 2008;82(12):5887-5911.
34. Yue HY, et al. Hepatocyte nuclear factor 4a attenuates hepatic fibrosis in rats. Gut. 2010;59(2):236-246.
35. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic β cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell. 2012;150(6):1223-1234.
36. Nam YJ, Song K, Olson EN. Heart repair by cardiac reprogramming. Nat Med. 2013;19(4):413-415.
37. Bures JBO, Huston JP. Innate and motivated behavior. In: Techniques and Basic Experiments for the Study of Brain and Behavior. New York, New York, USA: Elsevier; 1976:37-45.
38. Berry MN, Friend DS. High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J Cell Biol. 1969;43(3):506-520.
39. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol. 1976;13:29-83.
40. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105-1111.
41. Lajugie J, Bouhassira EE. GenPlay, a multipurpose genome analyzer and browser. Bioinformatics. 2011;27(14):1889-1893.
42. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30(10):e47.
43. Jago MV. The development of the hepatic megalocytosis of chronic pyrrolizidine alkaloid poisoning. Am J Pathol. 1969;56(3):405-421.
44. Laconi E, et al. Long-term, near-total liver replacement by transplantation of isolated hepatocytes in rats treated with retrorsine. Am J Pathol. 1998;153(1):319-329.
45. Peterson JE. Effects of the pyrrolizidine alkaloid, lasiocarpine N-oxide, on nuclear and cell division in the liver rats. J Pathol Bacteriol. 1965;89:153-171.